Purpose: Cortical glucose metabolism, brain amyloid β accumulation and hippocampal atrophy imaging have all been suggested as potential biomarkers in predicting which patients with mild cognitive impairment (MCI) will convert to Alzheimer’s disease (AD). The aim of this study was to compare the prognostic ability of [11C]PIB PET, [18F]FDG PET and quantitative hippocampal volumes measured with MR imaging in predicting conversion to AD in patients with MCI. Methods: The study group comprised 29 patients with MCI who underwent [11C]PIB PET and MR imaging. Of these, 22 also underwent [18F]FDG PET. All subjects were invited back for clinical evaluation after 2 years. Results: During the follow-up time 17 patients had converted to AD while 12 con...
Abstract: The biomarker-based new diagnostic criteria have been proposed for Alzheimer's disease (AD...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Purpose: Cortical glucose metabolism, brain amyloid β accumulation and hippocampal atrophy imaging h...
Purpose: We aimed to identify the cortical regions where hypometabolism can predict the speed of con...
Purpose: Mild cognitive impairment (MCI) is a transitional pathological stage between normal ageing ...
OBJECTIVES: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures wi...
Abstract Assessments of brain glucose metabolism (18F-FDG-PET) and cerebral amyloid burden (11C-PiB...
Abstract Assessments of brain glucose metabolism (18F-FDG-PET) and cerebral amyloid burden (11C-PiB...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
This project compares three neuroimaging biomarkers to predict progression to dementia in subjects w...
The aim of this study is to identify mild cognitive impairment (MCI) due to Alzheimer’s disease (AD)...
PURPOSE: The purpose of the study is to evaluate the combined accuracy of episodic memory performan...
Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures wi...
The aim of this study is to identify mild cognitive impairment (MCI) due to Alzheimer's disease (AD)...
Abstract: The biomarker-based new diagnostic criteria have been proposed for Alzheimer's disease (AD...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Purpose: Cortical glucose metabolism, brain amyloid β accumulation and hippocampal atrophy imaging h...
Purpose: We aimed to identify the cortical regions where hypometabolism can predict the speed of con...
Purpose: Mild cognitive impairment (MCI) is a transitional pathological stage between normal ageing ...
OBJECTIVES: To investigate whether the combination of fluoro-2-deoxy-d-glucose (FDG) PET measures wi...
Abstract Assessments of brain glucose metabolism (18F-FDG-PET) and cerebral amyloid burden (11C-PiB...
Abstract Assessments of brain glucose metabolism (18F-FDG-PET) and cerebral amyloid burden (11C-PiB...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
This project compares three neuroimaging biomarkers to predict progression to dementia in subjects w...
The aim of this study is to identify mild cognitive impairment (MCI) due to Alzheimer’s disease (AD)...
PURPOSE: The purpose of the study is to evaluate the combined accuracy of episodic memory performan...
Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures wi...
The aim of this study is to identify mild cognitive impairment (MCI) due to Alzheimer's disease (AD)...
Abstract: The biomarker-based new diagnostic criteria have been proposed for Alzheimer's disease (AD...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...
Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical phase o...